Physician profile
Anthony H Sin
NPI 1073738613
$1,541,636.45
in general payments reported to CMS, 2019-2025
25 companies · $764K in 2025
The $764K reported for 2025 was more than what 99% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $13K · 2021: $49K · 2022: $121K · 2023: $61K · 2024: $518K · 2025: $764K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1.3M · Food and Beverage: $3,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,339,800.00 |
| Food and Beverage | $3,514.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| L&K Biomed Co. , Ltd. | $711,000.00 | 2024-2025 | |
| Medyssey USA, INC | $696,877.25 | 2019-2025 | |
| Gs Solutions, INC. | $98,518.05 | 2021-2025 | |
| Aegis Spine, INC. | $27,031.65 | 2020-2022 | |
| Medtronic USA, INC. | $2,565.37 | 2019-2020 | |
| Sanara Medtech INC. | $1,438.65 | 2021-2022 | |
| Medtronic, INC. | $1,359.20 | 2021-2025 | Mazor X System, Unid_pass, Strata |
| Globus Medical, INC. | $1,304.06 | 2019-2020 | |
| Stryker Corporation | $377.07 | 2019-2022 | |
| Depuy Synthes Sales INC. | $286.83 | 2019-2022 | |
| Kerecis Limited | $203.66 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Si-Bone, INC. | $186.86 | 2021-2023 | |
| Lifenet Health | $80.05 | 2025 | Pliafx Flo |
| Brainlab, INC. | $68.92 | 2022 | |
| Spine Wave, INC. | $67.79 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cerapedics INC. | $65.08 | 2025 | I-Factor Peptide Enhanced Bone Graft |
| Pacira Pharmaceuticals Incorporated | $41.46 | 2022 | |
| Implanet America, INC. | $39.21 | 2024 | |
| Integra Lifesciences Corporation | $33.61 | 2020 | |
| Merck Sharp & Dohme LLC | $17.21 | 2022 | |
| Smith+Nephew, INC. | $17.09 | 2024 | Stravix |
| Providence Medical Technology, INC. | $16.16 | 2025 | |
| Axogen | $15.83 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.42 | 2021 | |
| Zimmer Biomet Holdings, INC. | $10.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$448,987.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Sin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.